Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 8, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

July 31, 2026

Conditions
Hereditary Hemorrhagic TelangiectasiaEpistaxisAnemiaNosebleedHHT
Interventions
DRUG

Pazopanib

gel capsule, with 25mg-similar fills

DRUG

Placebo oral capsule

identical gel capsule without active pharmaceutical ingredient

Trial Locations (11)

21287

John Hopkins University, Baltimore

27514

University of North Carolina, Chapel Hill

30912

Augusta University, Augusta

44195

Cleveland Clinic, Cleveland

55905

Mayo Clinic, Rochester

63110

Washington University, St Louis

75390

University of Texas - Southwestern, Dallas

80045

University of Colorado, Denver

84132

University of Utah Medical Center, Salt Lake City

90095

University of California - Los Angeles, Los Angeles

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Cure HHT

OTHER